The United States Food and Drug Administration (US FDA) has issued Establishment Inspection Report (EIR) to Aurobindo Pharma’s Unit III, a Formulation manufacturing facility situated at Bachupally Village, Medchal Malkajgiri District, Telangana. The said facility classified as Voluntary Action Indicated (VAI).
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
